On the contrary, it has been reported that in control subjects and allergic rhinitis patients, intranasal administrations of Lyso-PAF did not increase the reactivity of the nasal airway in response to histamine [13] nor induced nasal symptoms or nasal airway resistance [9]. The gene discussed is PCLAF; the disease is allergic rhinitis.